Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open‑label crossover pharmacodynamic study of TAK-438 vs esomeprazole or rabeprazole in healthy Japanese males
jRCT2080222361Phase 3
- Sponsor
- Takeda
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vonoprazan in Peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) (3 arms), sponsored by Takeda. Primary endpoint: Acid-inhibitory effect of TAK-438 versus esomeprazole or rabeprazole.
02
Drugs
vonoprazan
03
Conditions
Peptic ulcer disease (PUD)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on jRCT2080222361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222361.